Skip to main content
2025 CMHC Annual Event Main banner
Back

Patrick M. Moriarty, MD, FACP, FACC, FNLA, FESC

Director of Atherosclerosis and Lipoprotein-apheresis Center Pharmacology
The University of Kansas Health System
Kansas University Medical Center
Kansas City, Kansas, United States

Patrick M. Moriarty, MD is a Professor of Medicine at The University of Kansas Medical Center in Kansas City, Kansas. He is the Director of Clinical Pharmacology and the Atherosclerosis & Lipid-Apheresis Center. He earned his Doctorate in Medicine and Surgery at the University of Rome School of Medicine and Surgery in Italy and completed his residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center.

Dr. Moriarty is a fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, National Lipid Association, and he was the 2014-2015 president of the International Society for Apheresis. He serves as a manuscript reviewer for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis and Clinical Lipidology.

Dr. Moriarty has published over 150 peer-reviewed articles/chapters. His research activities include atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia, and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, dementia, and diabetes. Moreover, Dr. Moriarty is a scientific advisory board member for the FH Foundation. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease. The University of Kansas Lipoprotein-Apheresis Center is the largest in North America for treating Familial Hypercholesterolemia and elevated Lp(a).

Disclosure information not submitted.

Presentation(s):